Results 121 to 130 of about 47,200 (309)
Annals of Noninvasive Electrocardiology, Volume 30, Issue 4, July 2025.ABSTRACT Background Ablation of the cavo‐tricuspid isthmus (CTI) is the standard treatment for typical atrial flutter. High‐power strategies have been described to improve lesion efficacy and durability. Objective To compare the acute success, safety, and long‐term outcomes of two strategies of high‐power CTI ablation using 8‐mm gold‐tip nonirrigated ...
Wael Zaher +3 more
wiley +1 more source
Dabigatran experience in primary and secondary prevention of cardioembolic stroke
Неврология, нейропсихиатрия, психосоматика, 2013 The review of novel oral anticoagulants (dabigatran, rivaroxaban and apixaban) in stroke prevention and also own data of administration of dabigatran in primary and secondary prevention of ischemic stroke in 45 patients with cerebrovascular diseases are ...
Maksim Alekseyevich Domashenko +3 more
doaj +1 more source
Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C [PDF]
, 2014 AIMS: Dabigatran is largely cleared by renal excretion. Renal function is thus a major determinant of trough dabigatran concentrations, which correlate with the risk of thromboembolic and haemorrhagic outcomes.
Berit P. Jensen +8 more
core +1 more source
JAMA Network Open, 2019 Importance Uninterrupted dabigatran therapy reduces stroke risk in patients with nonvalvular atrial fibrillation (NVAF) undergoing ablation and is associated with a lower bleeding risk than uninterrupted warfarin therapy.
A. Nogami +13 more
semanticscholar +1 more source
Diabetes, Obesity and Metabolism, Volume 27, Issue 7, Page 3869-3881, July 2025.Abstract Aims There is limited evidence regarding whether obesity modifies the association between the use of sodium‐glucose cotransporter 2 inhibitors (SGLT2is) and the risk of cardiovascular events. We assessed whether baseline body mass index (BMI) modifies the association between SGLT2i use and the risk of major adverse cardiovascular events (MACE)
Hwa Yeon Ko +7 more
wiley +1 more source
Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
Trauma Case Reports, 2021 Dabigatran is an oral anticoagulant directly acting as thrombin inhibitor. The monoclonal antibody idarucizumab was developed to reverse its anticoagulatory effects after application of a standardized dose.
Mathias Ströhle +4 more
doaj
Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
Health and Quality of Life Outcomes, 2017 Background Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource ...
Shannon L. Reynolds +9 more
doaj +1 more source
Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation [PDF]
, 2013 ObjectivesThis study sought to compare the net clinical benefit of dabigatran 110 mg bid and 150 mg bid with that of warfarin in patients with atrial fibrillation (AF).BackgroundIn patients with AF, dabigatran 110 mg bid and 150 mg bid are associated ...
Connolly, Stuart J. +7 more
core +1 more source
Annals of Neurology, Volume 97, Issue 6, Page 1205-1214, June 2025.Objectives Intravenous thrombolysis (IVT) is contraindicated for acute ischemic stroke (AIS) patients taking direct oral anticoagulants (DOACs) within 48 hours before index stroke. Limited data exist on off‐label use of IVT for these patients. We compared the safety and outcomes of IVT in AIS patients with DOAC treatment and patients with no OAC before
Marius Matusevicius +11 more
wiley +1 more source
Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]
, 2018 © The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast +66 more
core +1 more source